Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Growth Paris  >  Cellectis    ALCLS   FR0010425595

CELLECTIS

(ALCLS)
  Report
Real-time Quote. Real-time Euronext Growth Paris - 01/18 11:35:02 am
26.25 EUR   +2.94%
01/14European ADRs Climb Higher in Thursday Trading
MT
01/13European ADRs Move Lower in Wednesday Trading
MT
01/11European ADRs Move Sharply Lower in Monday Trading
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • For a short-term investment strategy, the company has poor fundamentals.
Strengths
  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Within the weekly time frame the stock shows a bullish technical configuration above the support level at 13.68 EUR
Weaknesses
  • Stock prices approach a strong long-term resistance in weekly data at EUR 26.25.
  • Technically, the stock approaches a strong medium-term resistance at EUR 26.7.
  • Low profitability weakens the company.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • Based on current prices, the company has particularly high valuation levels.
Ratings chart
Sector Biotechnology & Medical Research - NEC
1st jan.Capitalisation (M$)Investor Rating
CELLECTIS4.51%1 319
MODERNA, INC.24.10%51 304
LONZA GROUP AG3.27%49 041
CELLTRION, INC.-12.53%40 715
IQVIA HOLDINGS INC.4.81%36 004
SEAGEN INC.6.06%33 601
HANGZHOU TIGERMED CONSULTIN..0.43%21 655
INCYTE CORPORATION4.12%19 832
ALNYLAM PHARMACEUTICALS, IN..28.00%19 328
PHARMARON BEIJING CO., LTD.5.47%15 119
CRISPR THERAPEUTICS AG30.55%14 233
CHARLES RIVER LABORATORIES ..9.55%13 616
BIO-TECHNE CORPORATION9.50%13 425
PPD, INC.6.66%12 762
QIAGEN N.V.0.66%12 098
ICON PUBLIC LIMITED COMPANY7.88%11 101
More Results
Financials
Sales 2020 53,4 M 64,5 M 64,5 M
Net income 2020 -74,3 M -89,7 M -89,7 M
Net cash 2020 161 M 194 M 194 M
P/E ratio 2020 -9,26x
Yield 2020 -
Capitalization 1 091 M 1 319 M 1 317 M
EV / Sales 2020 17,4x
EV / Sales 2021 15,1x
Nbr of Employees 259
Free-Float 83,2%
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio -
Potential
Yield -
Consensus -
7 days EPS revision
4 months EPS revision -
1 year EPS revision -
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes